Market research
VETO.PA Vetoquinol SA
PA EUR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 910M
- P/E ratio
- 14.39
- Analyst target
- 91.5
- Dividend yield
- 1.2%
- Beta
- 0.83
Profile
Instrument facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- FR0004186856
- Market cap
- 910M
- P/E ratio
- 14.39
- Analyst target
- 91.5
- Dividend yield
- 1.2%
- Beta
- 0.83
About
About Vetoquinol SA
Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA operates as a subsidiary of Soparfin SCA.
Research context
Vetoquinol SA appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the VETO.PA discussion.
5 years, 6 months ago
Vetoquinol SA is currently in a long term uptrend where the price is trading 12.6% above its 200 day moving average.
From a valuation standpoint, the stock is 98.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.0.
Vetoquinol SA's total revenue sank by 0.0% to $106M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $8M since the same quarter in the previous year.
Finally, its free cash flow fell by 34.2% to $15M since the same quarter in the previous year.
Based on the above factors, Vetoquinol SA gets an overall score of 2/5.